{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:48Z","timestamp":1786649928585,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the front-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). Beyond their long-term effects and safety profile, they are a landmark of precision medicine in the history of NSCLC. Regarding safety outcomes, EGER TKIs differ from cytotoxic chemotherapy as they may cause dermatological adverse events, diarrhea, and fetal interstitial pneumonitis. They are mainly metabolized by the liver and to a lesser extent by the kidney and are therefore considered relatively safe to use, even in patients with renal impairment. Moreover, renal adverse events have been rarely described in patients treated with TKIs; in particular, only a few cases of EGFR TKI-induced IgA nephropathy have been reported. Herein, we report a case of EGFR TKI-induced tubulointerstitial nephritis and IgA nephropathy, aggravating renal function with short-term EGFR TKI use in EGFR-mutant NSCLC.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_430_24","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T17:09:46Z","timestamp":1743700186000},"page":"292-294","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Case report of short term EGFR TKI induced tubulointerstitial nephritis and IgA nephropathy in a patient with advanced non small cell lung cancer"],"prefix":"10.4103","volume":"21","author":[{"given":"Ji Eun","family":"Park","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemin","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Wha","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Gun","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hui","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"R1-20250403","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"R2-20250403","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.12998\/wjcc.v10.i19.6360","article-title":"Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis","volume":"10","author":"Lan","year":"2022","journal-title":"World J Clin Cases"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13730-014-0135-0","article-title":"A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma","volume":"4","author":"Kaneko","year":"2015","journal-title":"CEN Case Rep"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.54.3661","article-title":"Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib","volume":"54","author":"Maruyama","year":"2015","journal-title":"Intern Med"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10157-008-0066-1","article-title":"Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib","volume":"12","author":"Masutani","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"e31219","DOI":"10.1097\/MD.0000000000031219","article-title":"IgA nephropathy pathogenesis and therapy: Review &updates","volume":"101","author":"Habas","year":"2022","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_430_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:03Z","timestamp":1786647603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_430_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_430_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}